Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Braeburn Gets CRL For CAM2038 In Opioid Use Disorder, Yields Ground To Indivior

Executive Summary

Braeburn was in a position to launch its buprenorphine injection CAM2038 within a month and a half of its Jan. 19 PDUFA date, putting the opioid addiction therapy on the market around the same time as Indivior's Sublocade, but now there may be several months between the products' launches.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts